The Maryland Prescription Drug Affordability Board (PDAB) is an independent state agency working to protect Marylanders—and the broader health care system—from the burden of high prescription drug costs. To do this, the PDAB conducts Cost Review Studies to identify medications that pose affordability challenges and can recommend solutions, including setting upper payment limits to reduce costs.
The Board is currently reviewing six high-impact drugs—Farxiga, Jardiance, Ozempic, Trulicity, Dupixent, and Skyrizi—and expects to complete Cost Review Studies starting this spring. If any of these drugs are found to create affordability challenges, the Board will begin the Policy Review Process as early as this summer.